Epigallocatechin-3-gallate prevents inflammation and diabetes -Induced glucose tolerance through inhibition of NLRP3 inflammasome activation

Cheng Zhang,Xin Li,Xiang Hu,Qirui Xu,Yanqi Zhang,Hongyan Liu,Yutao Diao,Xiaoyu Zhang,Lianlian Li,Jie Yu,Haipeng Yin,Jun Peng

DOI: https://doi.org/10.1016/j.intimp.2021.107412

IF: 5.714

2021-04-01

International Immunopharmacology

Abstract:<p>Epigallocatechin-3-gallate (EGCG), the primary polyphenol component of green tea, has been shown to inhibit both oxidation and inflammation. However, the exact mechanism through which EGCG exhibits anti-inflammatory effects remains unclear. In this study, we assessed the potential pathways by which EGCG regulates NLRP3 inflammasome activity in vitro. We found that EGCG inhibits caspase-1 activation and IL-1β secretion by suppressing NLRP3 inflammasome activation in mouse bone marrow-derived macrophages (BMDMs). EGCG was also observed to block NLRP3-mediated ASC speckle formation and to alleviate pyroptosis in BMDMs. In addition, EGCG treatment could improve high-fat diet (HFD)-induced glucose tolerance and prevent NLRP3 inflammasome-dependent inflammation in a mouse model of HFD-induced type 2 diabetes (T2D). Taken together, our results show that EGCG is a general inhibitor of NLRP3 inflammasome activation and administration of EGCG in T2D mice could improve glucose tolerance <em>in vivo</em>.</p>

pharmacology & pharmacy,immunology

What problem does this paper attempt to address?

The problem this paper attempts to address is how epigallocatechin gallate (EGCG) can prevent inflammation and glucose intolerance induced by diabetes by inhibiting the activation of the NLRP3 inflammasome. Specifically, the researchers evaluated the potential pathways through which EGCG regulates NLRP3 inflammasome activity in vitro and validated the inhibitory effect of EGCG on NLRP3 inflammasome-dependent inflammation and its improvement on glucose tolerance in a high-fat diet-induced type 2 diabetes mouse model.

### Main Research Content:
1. **EGCG Inhibits the Initial Activation of the NLRP3 Inflammasome**:
- The study found that EGCG can dose-dependently inhibit LPS-induced caspase-1 activation and pro-IL-1β expression, thereby inhibiting the initial activation of the NLRP3 inflammasome.

2. **EGCG Inhibits Caspase-1 Activation and IL-1β Secretion**:
- Through further experiments, the researchers confirmed that EGCG can prevent caspase-1 activation and IL-1β secretion by inhibiting the activation of the NLRP3 inflammasome.

3. **Inhibitory Effect of EGCG in Mouse and Human Macrophages**:
- EGCG not only showed an inhibitory effect on the NLRP3 inflammasome in mouse bone marrow-derived macrophages (BMDMs) but also exhibited a similar inhibitory effect in human THP-1 macrophages.

4. **Mechanism of EGCG Inhibition of NLRP3 Inflammasome Activation**:
- The study found that EGCG inhibits the activation of the NLRP3 inflammasome by interfering with mitochondrial spatial arrangement, reducing ASC oligomerization and speck formation. Additionally, EGCG can alleviate pyroptosis caused by the NLRP3 inflammasome.

5. **EGCG Improves Glucose Tolerance in High-Fat Diet-Induced Type 2 Diabetes Mice**:
- In a high-fat diet-induced type 2 diabetes mouse model, EGCG supplementation significantly improved glucose tolerance. In vitro experiments also showed that EGCG could inhibit caspase-1 activation and IL-1β secretion in BMDMs.

### Conclusion:
Through the above studies, the authors demonstrated that EGCG is an effective NLRP3 inflammasome inhibitor that can inhibit inflammatory responses through multiple pathways and improve glucose tolerance in high-fat diet-induced type 2 diabetes mice. These findings provide new theoretical support for the application of EGCG in the treatment of metabolic diseases.